Kindora
FeaturesSocial Impact InvestmentsPricing
AboutLive Demos
Sign InSign Up
    Kindora
    FeaturesSocial Impact InvestmentsPricing
    AboutLive Demos
    Sign InSign Up
    1. Home
    3. Foundations
    5. Institute for the Study of Aging
    Institute for the Study of Aging logo

    Institute for the Study of Aging

    Active
    NEW YORK, NYWebsite2129018000EIN: 13-40241492 filings on record

    About Institute for the Study of Aging

    To rapidly accelerate the development of drugs to prevent, treat and cure Alzheimer’s disease through venture philanthropy investments in translational research and diagnostics.

    Focus Areas

    Alzheimer's disease and related dementiasDrug discovery and developmentBiomarkers (blood, CSF, neuroimaging, digital)Diagnostics development (Diagnostics Accelerator)Prevention researchNeuroinflammationProteostasisSenescenceNeuroprotectionDigital biomarkers

    Who They Fund

    people living with Alzheimer's disease and related dementiasolder adults

    About Institute for the Study of Aging

    Institute for the Study of Aging Inc centers its giving on Alzheimer’s drug discovery, with one recent grant accounting for almost the full amount of annual grants on file: $383,769 to the Alzheimer’s Drug Discovery Foundation in New York for research on Alzheimer’s drug discovery. That single award points to a highly specialized funder rather than a broad generalist grantmaker. The foundation’s active programs show a similar pattern of mission-focused research support: therapeutic funding streams, biomarker development, and diagnostics initiatives are all built around translational work that moves ideas toward clinical use. The foundation also made smaller awards in the same research lane, including $2,000 to the Association for Frontotemporal Degeneration in King of Prussia, Pennsylvania, and $100 to Historic House Trust in New York. Across its current programs, the emphasis stays on Alzheimer’s disease and related dementias, with support for drug development, biomarkers, diagnostics, and prevention research. The grants are project-based and tied to specific scientific aims rather than broad operating support, with a recurring emphasis on translational and therapeutic development.

    What Institute for the Study of Aging Funds

    The foundation’s cause areas cluster around translational Alzheimer’s research. In drug development, its Therapeutics Funding Programs support IND-enabling studies, early-stage clinical trials, and lead optimization for new therapies. Its Biomarkers RFP backs work to validate established and novel biomarkers, including PET, CSF, MRI, and EEG/MEG/TMS approaches, with a defined context of use and a path to commercialization. Diagnostics are another clear lane. The Diagnostics Accelerator portfolio supports early, accurate, and affordable Alzheimer’s diagnostics through peripheral biomarkers, digital biomarkers, and biobank sharing. Within that portfolio, the Digital Biomarkers RFP funds digital tools and apps, speech measures, and other digital signatures used in diagnosis, progression tracking, and clinical trial enrichment. Prevention research is also part of the program mix through the Therapeutics Funding Programs.

    How Institute for the Study of Aging Gives

    Typical grant size is sharply skewed: p25 is $1,050, median is $2,000, and p75 is $192,884. That spread reflects a mix of very small awards and a much larger research grant. The recent record also shows repeat support within the same year for New York recipients, while the broader program structure is project-based and research-specific rather than individual giving. The foundation uses request-for-proposals in several active programs, and multiple streams accept unsolicited applications. Other initiatives, including the Collaborative CNS Screening Initiative, are invitation-based or otherwise not open in the same way. Its active portfolio includes both grant programs and an annual prize, which is a different funding mechanism from project awards.

    Financial Snapshot

    Annual Giving

    $386K

    Total Assets

    $0

    Total Revenue

    $40K

    Total Expenses

    $180K

    Typical Grant Size

    Most grants fall between $1K and $193K, with a median of $2K.

    25th Percentile

    $1K

    Median

    $2K

    75th Percentile

    $193K

    Geographic Reach

    Regional2 states funded

    About 67% of grants go to recipients in NY.

    Funding intensity
    Low
    High
    Headquarters

    Deep Analysis

    Unlock Deep Analysis

    Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.

    Get Started Free

    Similar Funders

    See Similar Funders

    Free Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.

    Get Started Free

    Want a Personalized Pitch for Institute for the Study of Aging?

    Sign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.

    Get Started FreeView Pricing
    Free plan available
    No contracts
    Cancel anytime
    Free Weekly Newsletter

    The Grant Brief

    Weekly grant intelligence for social impact leaders. Curated opportunities, funding trends, and strategic insights — free.

    Join 500+ social impact leaders. Unsubscribe anytime. Privacy Policy

    Trusted by mission-driven teams at organizations nationwide

    Kindora Logo

    At Kindora, we combine data-driven insights with a human touch to create meaningful, strategic fundraising solutions for mission-driven organizations of all sizes.

    Get The Grant Brief — free weekly grant intelligence

    Quick Links

    • Features
    • Social Impact Investments
    • About Us
    • Mission
    • How It Works
    • Pricing
    • Sales deck
    • Philanthropy Jobs
    • Nonprofit Compensation
    • Live demo (every plan)
    • Individual prospecting demoBeta
    • Blog
    • FAQ
    • Getting Started

    Connect With Us

    LinkedInTwitterFacebook

    © 2026 Kindora. All rights reserved.

    Privacy PolicyTerms of ServiceSystem Status
    See If You're a Fit — FreeFree account · instant fit score · similar funders
    biomedical research community (scientists, drug developers)

    Funding Style

    research grantstranslational/therapeutic developmentdisease-specific fundingproject-based funding

    Topics

    Alzheimer's disease researchdrug discovery and developmentneuroscience/neuropathologypreclinical-to-clinical therapeutic translation

    Where Institute for the Study of Aging Makes Grants

    Giving is regional, but the recipient footprint is concentrated in New York. New York recipients account for 67% of grants, and the latest grants include two New York City recipients. Outside New York, the recent record includes King of Prussia, Pennsylvania. The broader active programs extend beyond the United States in some cases, with global or worldwide grant geographies listed across therapeutic, biomarker, and diagnostics initiatives. Recent recipient-country data is entirely U.S.-based in the sample on file.

    Frequently Asked Questions About Institute for the Study of Aging

    What areas does Institute for the Study of Aging Inc fund most directly?

    Its current programs focus on Alzheimer’s disease and related dementias, especially drug discovery and development, biomarkers, diagnostics development, and prevention research. The active portfolio also includes neuroimaging, CSF biomarkers, digital biomarkers, neuroinflammation, proteostasis, senescence, and neuroprotection.

    What is the typical grant size?

    The distribution is highly uneven: the 25th percentile is $1,050, the median is $2,000, and the 75th percentile is $192,884. That pattern shows many smaller project awards alongside some much larger research grants.

    Does the foundation accept unsolicited applications?

    Yes for several active RFP-based programs, including Therapeutics Funding Programs, Biomarkers RFP, the FTD RFP, and the ADDF-Harrington Scholar Program. Some other initiatives, such as the Collaborative CNS Screening Initiative and the Diagnostics Accelerator portfolio, are not listed as accepting unsolicited applications.

    Where does the foundation give most often?

    New York is the top state by grant count, and 67% of grants go to recipients in New York. Recent grants include recipients in New York City as well as King of Prussia, Pennsylvania.

    What kinds of funding mechanisms does it use?

    The foundation uses project-based research funding, RFPs, and an annual prize. Its active programs include therapeutic and biomarker RFPs, diagnostics initiatives, and the Melvin R. Goodes Prize, which is an unrestricted monetary award of $150,000.

    Latest 990 Filing

    2024

    Source: IRS Form 990-PF, fiscal year 2024.

    Open Grant Opportunities

    Current and upcoming funding from Institute for the Study of Aging that your nonprofit may be able to apply for.

    Open nowCloses Jul 20, 2026Award: Up to $300K

    Accelerating Drug Discovery for Frontotemporal Degeneration (FTD) RFP

    Drug discoveryLead optimizationIn vivo efficacy+15 more

    Who can apply: Open to researchers and clinicians in the U.S. and worldwide at academic medical centers, universities, nonprofits, and biotechnology companies. Industry partnerships are encouraged. Biotechnology companies must demonstrate a clear need for nonprofit funding; existing companies and new spinouts are eligible. Funding is structured as mission-related investments with case-by-case return on investment terms.

    Deadline: Letter of Intent: Date has passed; Invited Full Proposal: July 20, 2026

    View & apply
    Open nowCloses Sep 14, 2026Award: Up to $600K

    Biomarkers RFP (ADDF Biomarkers Funding Opportunity)

    Neuroimaging (PET, MRI, MRS)CSF biomarkersFunctional activity measures (EEG/MEG/TMS)+4 more

    Who can apply: Open to academic centers, universities, nonprofits, and biotech companies worldwide. Projects must demonstrate human proof-of-concept data for proposed biomarker and a clear context of use.

    Deadline: Invited Full Proposal: January 12, 2026. Future LOI/Full Proposal dates listed (e.g., LOI Sept 14, 2026; invited full proposal TBD).

    View & apply
    Open nowRolling / open intakeAward: Varies

    SpeechDx

    Speech biomarkersDigital biomarkersEarly detection+4 more

    Who can apply: Researchers, companies, and other entities may apply to access SpeechDx data for speech biomarker development. Applications are assessed for alignment with the initiative's mission and ethical requirements. Access is non-exclusive and subject to venture philanthropy terms.

    Deadline: Data access applications accepted on an ongoing basis; first data release began in Q1 2025 and batches continue quarterly until Q4 2027

    View & apply
    Open nowRolling / open intakeAward: Varies

    Diagnostics Accelerator (ADDF Diagnostics Accelerator initiative)

    Blood biomarkersPeripheral biomarkersEye/retinal biomarkers+10 more

    Who can apply: The program makes awards globally to academic institutions and biotech companies. Proposals are evaluated by scientific, regulatory, and business expertise. The program accepts proposals on a rolling basis and encourages applications for blood and other peripheral markers and digital biomarkers.

    Deadline: Rolling basis; no fixed deadline stated

    View & apply

    Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.

    Create a free account

    Deadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.

    Recent Grants

    Most recent grants reported to the IRS.

    RecipientLocationAmountYearPurpose
    ALZHEIMER'S DRUG DISCOVERY FOUNDATIONNEW YORK, NY$383,7692023RESEARCH ON ALZHEIMER'S DRUG DISCOVERY
    ASSOCIATION FOR FRONTOTEMPORAL DEGENERATIONKING OF PRUSSIA, PA$2,0002023RESEARCH ON ALZHEIMER'S DRUG DISCOVERY
    HISTORIC HOUSE TRUSTNEW YORK, NY$1002023RESEARCH ON ALZHEIMER'S DRUG DISCOVERY

    ALZHEIMER'S DRUG DISCOVERY FOUNDATION

    $383,769
    NEW YORK, NY2023

    RESEARCH ON ALZHEIMER'S DRUG DISCOVERY

    ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION

    $2,000
    KING OF PRUSSIA, PA2023

    RESEARCH ON ALZHEIMER'S DRUG DISCOVERY

    HISTORIC HOUSE TRUST

    $100
    NEW YORK, NY2023

    RESEARCH ON ALZHEIMER'S DRUG DISCOVERY